Cipla Ltd Stock Price Today (NSE: CIPLA)
Fundamental Score
Cipla Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Cipla Ltd share price today is ₹1335.50, up +0.00% on NSE/BSE as of 20 February 2026. Cipla Ltd (CIPLA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.23L (Cr). The 52-week high for CIPLA share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 22.62x, CIPLA is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 17.77% and a debt-to-equity ratio of 0.01.
Cipla Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Cipla Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Cipla Share Price: A ROCE-Focused Financial Analysis
In the dynamic pharmaceutical sector, where innovation and regulatory approvals are paramount, efficient capital allocation distinguishes market leaders. This analysis focuses on the financial health of Cipla Ltd, particularly its Return on Capital Employed (ROCE), a key indicator of profitability and efficiency. The current Cipla share price stands at ₹1330.0, accompanied by a Price-to-Earnings (PE) ratio of 22.62 and an impressive ROCE of 22.72%. This report forms part of a comprehensive, 80-parameter fundamental audit verified by Sweta Mishra.
A company's ROCE reveals how effectively it generates profits from its invested capital. Cipla's 22.72% ROCE suggests strong efficiency in utilizing its resources, which is crucial for sustaining growth and delivering shareholder value. This high ROCE can be interpreted as a competitive advantage, contributing to a wider economic moat. By consistently generating high returns on invested capital, Cipla is better positioned to reinvest in research and development, expand its market reach, and defend its market share against competitors.
While PE ratios offer insight into market valuation, comparing ROCE with peer companies provides a deeper understanding of operational effectiveness. It would be useful to analyse how Cipla's ROCE stacks up against companies like Mankind Pharma Ltd. Even with similar growth figures, a firm with a higher ROCE has a better ability to extract the maximum value out of the capital deployed.
Assessing management quality is key to understanding the sustainability of ROCE. While
Mankind Pharma Ltd enjoys a reputation for prudent management, factors like dividend policy, reinvestment decisions, and debt management influence long-term ROCE. Cipla's management needs to maintain financial discipline and pursue strategic investments to continue generating similar or better returns. The stability and trend of Cipla's ROCE over time will be indicative of the robustness of its business model and its long-term competitive position within the pharmaceutical landscape.Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Cipla Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CIPLA across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (17.77%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (22.72%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (23.29%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 22.62 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Excellent EPS Growth (28.64% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (28.68% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (127.03x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹14019.84 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 54.52%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Low Promoter Commitment (29.21%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Cipla Ltd Financial Statements
Comprehensive financial data for Cipla Ltd including income statement, balance sheet and cash flow
About CIPLA (Cipla Ltd)
Cipla Ltd (CIPLA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹1.23L (Cr). Cipla Ltd has delivered a Return on Equity (ROE) of 17.77% and a ROCE of 22.72%. The debt-to-equity ratio stands at 0.01, reflecting the company's capital structure. Investors tracking CIPLA share price can monitor key metrics including P/E ratio, promoter holding of 29.21%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
CIPLA Share Price: Frequently Asked Questions
What is the current share price of Cipla Ltd (CIPLA)?
As of 20 Feb 2026, 06:10 am IST, Cipla Ltd share price is ₹1335.50. The CIPLA stock has a market capitalisation of ₹1.23L (Cr) on NSE/BSE.
Is CIPLA share price Overvalued or Undervalued?
CIPLA share price is currently trading at a P/E ratio of 22.62x, compared to the industry average of 31.77x. Based on this relative valuation, the Cipla Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of CIPLA share price?
The 52-week high of CIPLA share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Cipla Ltd share price?
Key factors influencing CIPLA share price include quarterly earnings growth (Sales Growth: 7.64%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Cipla Ltd a good stock for long-term investment?
Cipla Ltd shows a 5-year Profit Growth of 28.68% and an ROE of 17.77%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing in CIPLA shares.
How does Cipla Ltd compare with its industry peers?
Cipla Ltd competes with major peers in the Pharmaceuticals. Investors should compare CIPLA share price P/E of 22.62x and ROE of 17.77% against the industry averages to determine competitive standing.
What is the P/E ratio of CIPLA and what does it mean?
CIPLA share price has a P/E ratio of 22.62x compared to the industry average of 31.77x. Investors pay ₹23 for every ₹1 of annual earnings.
How is CIPLA performing according to Bull Run's analysis?
CIPLA has a Bull Run fundamental score of 59/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does CIPLA belong to?
CIPLA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Cipla Ltd share price.
What is Return on Equity (ROE) and why is it important for CIPLA?
CIPLA has an ROE of 17.77%, which indicates excellent management efficiency. ROE measures how efficiently Cipla Ltd generates profits from shareholders capital.
How is CIPLA debt-to-equity ratio and what does it indicate?
CIPLA has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk.
What is CIPLA dividend yield and is it a good dividend stock?
CIPLA offers a dividend yield of 0.85%, meaning you receive ₹0.85 annual dividend for every ₹100 invested in Cipla Ltd shares.
How has CIPLA share price grown over the past 5 years?
CIPLA has achieved 5-year growth rates of: Sales Growth 9.97%, Profit Growth 28.68%, and EPS Growth 28.64%.
What is the promoter holding in CIPLA and why does it matter?
Promoters hold 29.21% of CIPLA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Cipla Ltd.
What is CIPLA market capitalisation category?
CIPLA has a market capitalisation of ₹123060 crores, placing it in the Large-cap category.
How volatile is CIPLA stock?
CIPLA has a beta of N/A. A beta > 1 suggests the Cipla Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is CIPLA operating profit margin trend?
CIPLA has a 5-year average Operating Profit Margin (OPM) of 23.29%, indicating the company's operational efficiency.
How is CIPLA quarterly performance?
Recent quarterly performance shows Cipla Ltd YoY Sales Growth of 7.64% and YoY Profit Growth of 3.73%.
What is the institutional holding pattern in CIPLA?
CIPLA has FII holding of 24.54% and DII holding of 29.98%. Significant institutional holding often suggests professional confidence in the Cipla Ltd stock.